https://scholars.lib.ntu.edu.tw/handle/123456789/582029
標題: | Genomic variation-guided management in chronic hepatitis C | 作者: | Hsu C.-S. JIA-HORNG KAO |
關鍵字: | hepatitis C virus; IL28B SNP; individualized therapy; metabolic profiles; pegylated interferon; viral kinetics | 公開日期: | 2012 | 卷: | 6 | 期: | 4 | 起(迄)頁: | 497-506 | 來源出版物: | Expert Review of Gastroenterology and Hepatology | 摘要: | In 2009, several different research groups simultaneously identified the polymorphisms close to IL28B gene as an important predictor of therapeutic response for chronic hepatitis C (CHC) patients receiving interferon-based treatment using approaches of genome-wide association studies. They also found that these genetic variations were strongly associated with the spontaneous viral clearance of hepatitis C virus (HCV) infection. Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. All these lines of evidence usher in a new genomic era for the management of HCV infection. In this article, advances in recent genome-wide association studies regarding HCV infection, and their impacts on the management of CHC patients will be reviewed. In addition, the clinical usefulness of genomic variations on the addition of direct antiviral agents to current standard of care will be discussed. ? 2012 Expert Reviews Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865708127&doi=10.1586%2fegh.12.24&partnerID=40&md5=22d4873c3b94b63a1018361c56811bca https://scholars.lib.ntu.edu.tw/handle/123456789/582029 |
ISSN: | 1747-4124 | DOI: | 10.1586/egh.12.24 | SDG/關鍵字: | alpha interferon; boceprevir; interleukin 28; interleukin 29; major histocompatibility antigen class 1; peginterferon; peginterferon lambda; placebo; ribavirin; telaprevir; vaniprevir; amino acid substitution; antiviral therapy; CD4+ T lymphocyte; CD8+ T lymphocyte; cytokine production; gene; gene linkage disequilibrium; genetic association; genetic variability; genotype; hemolytic anemia; hepatitis C; human; IL28B gene; ITPA gene; liver fibrosis; liver transplantation; missense mutation; natural killer cell; nonhuman; review; seroconversion; single nucleotide polymorphism; unspecified side effect; viral clearance; Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Individualized Medicine; Interferon-alpha; Interleukins; Pharmacogenetics; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。